Pubblicazioni

Autori:

Bergamini, Corinna; Dolci, Giulia; Rossi, Andrea; Torelli, Flavia; Ghiselli, Luca; Trevisani, Laura; Vinco, Giulia; Truong, Stella; La Russa, Francesca; Golia, Giorgio; Molino, Annamaria; Benfari, Giovanni; Ribichini, Flavio Luciano

Titolo:

Left atrial volume in patients with HER2-positive breast cancer: One step further to predict trastuzumab-related cardiotoxicity

Anno:

2018

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

Clinical Cardiology

ISSN Rivista:

0160-9289

N° Volume:

41

Numero o Fascicolo:

3

Intervallo pagine:

349-353

Parole chiave:

Cardiotoxicity; Left Atrial Volume; Left Ventricular Dysfunction; Trastuzumab; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Breast Neoplasms; Cardiac Volume; Cardiotoxicity; Echocardiography; Female; Follow-Up Studies; Heart Atria; Humans; Male; Middle Aged; Prognosis; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Ventricular Dysfunction, Left; Ventricular Function, Left; Neoplasm Staging

Breve descrizione dei contenuti:

Background: Trastuzumab (TZ) therapy requires careful monitoring of left ventricular (LV) ejection fraction (LVEF) because it can be potentially cardiotoxic. However, LVEF is an imperfect parameter and there is a need to find other variables to predict cardiac dysfunction early. Left atrium (LA) enlargement has proven to be a powerful predictor of adverse outcomes in several disease entities. Hypothesis: Baseline LA volume enlargement might predict TZ-related LV dysfunction. Methods: HER2-positive breast cancer patients receiving TZ and undergoing transthoracic echocardiography at baseline and at follow-up every 3 months were retrospectively recruited. One-hundred sixty-two patients formed the study population. Results: Baseline LAVI was dilated in 14 patients (8.6%). Mean follow-up was 14 ± 4 months. Cardiotoxicity occurred in 24 patients (14.8%). LAVI was an independent predictor of TZ-induced LV dysfunction in a clinical model, after adjustment for age and hypertension (odds ratio per 5-mL/m2 LAVI increase: 1.34, 95% confidence interval: 1.03-1.82, P = 0.03); and in a hemodynamic model, including ventricular sizes and systolic blood pressure level (odds ratio per 5-mL/m2 LAVI increase: 1.34, 95% confidence interval: 1.01-1.81, P = 0.04). The predicted probability of developing cardiotoxicity increased progressively, in parallel with LAVI values. Conclusions: Baseline LA dilatation emerges as a condition associated with the development of cardiotoxicity in HER2-positive breast cancer patients treated with TZ.

Id prodotto:

107162

Handle IRIS:

11562/992047

ultima modifica:

16 novembre 2022

Citazione bibliografica:

Bergamini, Corinna; Dolci, Giulia; Rossi, Andrea; Torelli, Flavia; Ghiselli, Luca; Trevisani, Laura; Vinco, Giulia; Truong, Stella; La Russa, Francesca; Golia, Giorgio; Molino, Annamaria; Benfari, Giovanni; Ribichini, Flavio Luciano, Left atrial volume in patients with HER2-positive breast cancer: One step further to predict trastuzumab-related cardiotoxicity «Clinical Cardiology» , vol. 41 , n. 3 , 2018 , pp. 349-353

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo